VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$2.98 USD
-0.06 (-1.97%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.01 +0.03 (1.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VTGN 2.98 -0.06(-1.97%)
Will VTGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTGN
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Other News for VTGN
Is VTGN setting up for a drop? Fell Below 50 Day Moving Average shows up after slipping 1.97%
Crossed Above 50 Day Moving Average appears for VTGN after 4.83% move
50 Day Moving Average Resistance appears for VTGN after 0.34% move
Is VTGN gaining bearish strength? Fell Below 50 Day Moving Average shows up after plummeting 10.46%
Is VTGN positioned for a breakdown? Fell Below 20 Day Moving Average shows up after sliding 4.13%